Valvular & structural heart disease
Short- and Long-Term Outcomes in Patients With Thrombophilia Undergoing Transcatheter Closure of Patent Foramen Ovale
Authors' conclusion
After PFO closure, no differences were observed in long-term adverse outcomes between patients with and without thrombophilia.
Study context
- Population
- Patients undergoing transcatheter patent foramen ovale (PFO) closure with preprocedural thrombophilia screening (97.9% for cryptogenic stroke; mean age 56.4 years)
- Participants
- 669 patients
- Exposure
- Thrombophilia vs no thrombophilia
- Thrombophilian = 174
- Outcome
- Long-term adverse outcomes (rates per 100 person-years)
- Follow-up
- Median 11.6 years
Methodological detailsconsecutive patients, registry linked to population-based administrative databases, Ontario, Canada
- Consecutive patients
- Registry linked to population-based administrative databases
- Ontario, Canada
Main finding
As reported in the abstract
Long-term adverse outcomes
- New-onset AF (most common), overall rate per 100 person-years
- 1.0 (95% CI 0.8-1.2)
- Recurrent cerebrovascular events, overall rate per 100 person-years
- 0.8 (95% CI 0.6-1.1)
- No differences between the groups
- P > 0.05
Observational data: associations, not effects.
Further findings
30-day ED visits and readmissions
- No differences by thrombophilia status
Safety
In-hospital procedural complications
- Overall rate
- 3.1%
- No difference by thrombophilia status
Original publication
Short- and Long-Term Outcomes in Patients With Thrombophilia Undergoing Transcatheter Closure of Patent Foramen Ovale. JACC Cardiovasc Interv. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →